|
[1]
|
Ahmed, M. (2020) Gastrointestinal Neuroendocrine Tumors in 2020. World Journal of Gastrointestinal Oncology, 12, 791-807. [Google Scholar] [CrossRef] [PubMed]
|
|
[2]
|
Dasari, A., Shen, C., Halperin, D., et al. (2017) Trends in the Incidence, Prevalence, and Survival Outcomes in Patients with Neuroendocrine Tumors in the United States. JAMA Oncology, 3, 1335-1342. [Google Scholar] [CrossRef] [PubMed]
|
|
[3]
|
Yang, Z., Wang, W., Lu, J., et al. (2018) Gastric Neuroendocrine Tumors (G-Nets): Incidence, Prognosis and Recent Trend toward Improved Survival. Cellular Physiology and Biochemistry: International Journal of Experimental Cellular Physiology, Biochemistry, and Pharmacology, 45, 389-396. [Google Scholar] [CrossRef] [PubMed]
|
|
[4]
|
Strosberg, J.R., Benson, A.B., Huynh, L., et al. (2014) Clinical Benefits of Above-Standard Dose of Octreotide LAR in Patients with Neuroendocrine Tumors for Control of Carcinoid Syndrome Symptoms: A Multicenter Retrospective Chart Review Study. The Oncologist, 19, 930-936. [Google Scholar] [CrossRef] [PubMed]
|
|
[5]
|
Boyce, M. and Thomsen, L. (2015) Gastric Neuroendocrine Tumors: Prevalence in Europe, USA, and Japan, and Rationale for Treatment with a Gastrin/CCK2 Receptor Antagonist. Scandinavian Journal of Gastroenterology, 50, 550-559. [Google Scholar] [CrossRef] [PubMed]
|
|
[6]
|
Oberndorfer, S. (1907) Karzinoide Tumoren Des Dunndarms. Frankfurter Zeitschrift für Pathologie, 1, 426-430.
|
|
[7]
|
Rindi, G., Petrone, G. and Inzani, F. (2014) The 2010 WHO Classification of Digestive Neuroendocrine Neoplasms: A Critical Appraisal Four Years after Its Introduction. Endocrine Pathology, 25, 186-192. [Google Scholar] [CrossRef] [PubMed]
|
|
[8]
|
Nagtegaal, I.D., Odze, R.D., Klimstra, D., et al. (2020) The 2019 WHO Classification of Tumours of the Digestive System. Histopathology, 76, 182-188. [Google Scholar] [CrossRef] [PubMed]
|
|
[9]
|
CSCO神经内分泌肿瘤专家委员会. 中国胃肠胰神经内分泌肿瘤专家共识[J]. 临床肿瘤学杂志, 2013, 18(9): 815-832.
|
|
[10]
|
Rindi, G., Kl Ppel, G., Alhman, H., et al. (2006) TNM Staging of Foregut (Neuro)Endocrine Tumors: A Consensus Proposal Including a Grading System. Virchows Archiv: An International Journal of Pathology, 449, 395-401. [Google Scholar] [CrossRef] [PubMed]
|
|
[11]
|
Cancer AJCO (2012) AJCC Cancer Staging Atlas. Springer, New York.
|
|
[12]
|
Hoda, S.A. (2017) AJCC Cancer Staging Manua, 8th Edition. Advances in Anatomic Pathology, 24, 112-112. [Google Scholar] [CrossRef]
|
|
[13]
|
Amin, M.B., Greene, F.L., Edge, S.B., et al. (2017) The Eighth Edition AJCC Cancer Staging Manual: Continuing to Build a Bridge from a Population-Based to a More “Personalized” Approach to Cancer Staging. CA: A Cancer Journal for Clinicians, 67, 93-99. [Google Scholar] [CrossRef] [PubMed]
|
|
[14]
|
Delle Fave, G., Kwekkeboom, D.J., Van Cutsem, E., et al. (2012) ENETS Consensus Guidelines for the Management of Patients with Gastroduodenal Neoplasms. Neuroendocrinology, 95, 74-87. [Google Scholar] [CrossRef] [PubMed]
|
|
[15]
|
Sato, Y., Iwafuchi, M., Ueki, J., et al. (2002) Gastric Carcinoid Tumors without Autoimmune Gastritis in Japan: A Relationship with Helicobacter pylori Infection. Digestive Diseases and Sciences, 47, 579-585. [Google Scholar] [CrossRef]
|
|
[16]
|
Mastracci, L., Rindi, G., Grillo, F., et al. (2021) Neuroendocrine Neoplasms of the Esophagus and Stomach. Pathologica, 113, 5-11. [Google Scholar] [CrossRef]
|
|
[17]
|
Salyers, W.J., Vega, K.J., Munoz, J.C., et al. (2014) Neuroendocrine Tumors of the Gastrointestinal Tract: Case Reports and Literature Review. World Journal of Gastrointestinal Oncology, 6, 301-310. [Google Scholar] [CrossRef] [PubMed]
|
|
[18]
|
De Baere, T., Deschamps, F., Tselikas, L., et al. (2015) GEP-NETS Update: Interventional Radiology: Role in the Treatment of Liver Metastases from GEP-NETs. European Journal of Endocrinology, 172, R151-R166. [Google Scholar] [CrossRef]
|
|
[19]
|
Zhang, L., Ozao, J., Warner, R., et al. (2011) Review of the Pathogenesis, Diagnosis, and Management of Type I Gastric Carcinoid Tumor. World Journal of Surgery, 35, 1879-1886. [Google Scholar] [CrossRef] [PubMed]
|
|
[20]
|
Verbeek, W.H., Korse, C.M. and Tesselaar, M.E. (2016) GEP-NETs UPDATE: Secreting Gastro-Enteropancreatic Neuroendocrine Tumours and Biomarkers. European Journal of Endocrinology, 174, R1-R7. [Google Scholar] [CrossRef]
|
|
[21]
|
Borch, K., Stridsberg, M., Burman, P., et al. (1997) Basal Chromogranin A and Gastrin Concentrations in Circulation Correlate to Endocrine Cell Proliferation in Type-A Gastritis. Scandinavian Journal of Gastroenterology, 32, 198-202. [Google Scholar] [CrossRef] [PubMed]
|
|
[22]
|
Kanakisg, K. (2012) Biochemical Markers for Gastroenteropancreatic Neuroendocrine Tumours (GEP-NETs). Best Practice & Research Clinical Gastroenterology, 26, 791-802. [Google Scholar] [CrossRef] [PubMed]
|
|
[23]
|
Mj Nes, P., Sagatun, L., Nordrum, I.S., et al. (2017) Neuron-Specific Enolase as an Immunohistochemical Marker Is Better than Its Reputation. The Journal of Histochemistry and Cytochemistry: Official Journal of the Histochemistry Society, 65, 687-703. [Google Scholar] [CrossRef] [PubMed]
|
|
[24]
|
Birkenkamp-Demtr Der, K., Wagner, L., Brandt, S., Rensen, F., et al. (2005) Secretagogin Is a Novel Marker for Neuroendocrine Differentiation. Neuroendocrinology, 82, 121-138. [Google Scholar] [CrossRef] [PubMed]
|
|
[25]
|
Sundin, A., Arnold, R., Baudin, E., et al. (2017) ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: Radiological, Nuclear Medicine & Hybrid Imaging. Neuroendocrinology, 105, 212-244. [Google Scholar] [CrossRef] [PubMed]
|
|
[26]
|
王杨迪, 宋晨宇, 石思雅, 等. 胃肠胰神经内分泌肿瘤的影像学研究进展[J]. 放射学实践, 2020, 35(9): 1190-1195.
|
|
[27]
|
Modlin, I.M., Kidd, M. and Lye, K.D. (2002) Biology and Management of Gastric Carcinoid Tumours: A Review. The European Journal of Surgery, 168, 669-683. [Google Scholar] [CrossRef] [PubMed]
|
|
[28]
|
Srirajaskanthan, R., Kayani, I., Quigley, A.M., et al. (2010) The Role of 68Ga-DOTATATE PET in Patients with Neuroendocrine Tumors and Negative or Equivocal Findings on 111In-DTPA-Octreotide Scintigraphy. Journal of Nuclear Medicine: Official Publication, Society of Nuclear Medicine, 51, 875-882. [Google Scholar] [CrossRef] [PubMed]
|
|
[29]
|
Burkitt, M.D. and Pritchard, D.M. (2006) Review Article: Pathogenesis and Management of Gastric Carcinoid Tumours. Alimentary Pharmacology & Therapeutics, 24, 1305-1320. [Google Scholar] [CrossRef] [PubMed]
|
|
[30]
|
Sato, Y. (2015) Endoscopic Diagnosis and Management of Type I Neuroendocrine Tumors. World Journal of Gastrointestinal Endoscopy, 7, 346-353. [Google Scholar] [CrossRef] [PubMed]
|
|
[31]
|
Chin, J.L. and O’toole, D. (2017) Diagnosis and Management of Upper Gastrointestinal Neuroendocrine Tumors. Clinical Endoscopy, 50, 520-529. [Google Scholar] [CrossRef] [PubMed]
|
|
[32]
|
Roberto, G.A., Rodrigues, C.M.B., Peixoto, R.D., et al. (2020) Gastric Neuroendocrine Tumor: A Practical Literature Review. World Journal of Gastrointestinal Oncology, 12, 850-856. [Google Scholar] [CrossRef] [PubMed]
|
|
[33]
|
Luigi, I. (2016) An Update on the Pathology of Neuroendocrine Tumors. Frontiers in Bioscience, 8, Article No. 1. [Google Scholar] [CrossRef] [PubMed]
|
|
[34]
|
Wang, Y.H., Yang, Q.C., Lin, Y., et al. (2014) Chromogranin A as a Marker for Diagnosis, Treatment, and Survival in Patients with Gastroenteropancreatic Neuroendocrine Neoplasm. Medicine, 93, E247. [Google Scholar] [CrossRef]
|
|
[35]
|
O’toole, D., Grossman, A., Gross, D., et al. (2009) ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: Biochemical Markers. Neuroendocrinology, 90, 194-202. [Google Scholar] [CrossRef] [PubMed]
|
|
[36]
|
Garcia-Carbonero, R., Sorbye, H., Baudin, E., et al. (2016) ENETS Consensus Guidelines for High-Grade Gastroenteropancreatic Neuroendocrine Tumors and Neuroendocrine Carcinomas. Neuroendocrinology, 103, 186-194. [Google Scholar] [CrossRef] [PubMed]
|
|
[37]
|
Yuan, C.H., Wang, J., Xiu, D.R., et al. (2016) Meta-Analysis of Liver Resection versus Nonsurgical Treatments for Pancreatic Neuroendocrine Tumors with Liver Metastases. Annals of Surgical Oncology, 23, 244-249. [Google Scholar] [CrossRef] [PubMed]
|
|
[38]
|
Sundin, A. (2012) Radiological and Nuclear Medicine Imaging of Gastroenteropancreatic Neuroendocrine Tumours. Best Practice & Research Clinical Gastroenterology, 26, 803-818. [Google Scholar] [CrossRef] [PubMed]
|
|
[39]
|
Ozao-Choy, J., Buch, K., Strauchen, J.A., et al. (2010) Laparoscopic Antrectomy for the Treatment of Type I Gastric Carcinoid Tumors. The Journal of Surgical Research, 162, 22-25. [Google Scholar] [CrossRef] [PubMed]
|
|
[40]
|
Dias, A.R., Azevedo, B.C., Alban, L.B.V., et al. (2017) Gastric Neuroendocrine Tumor: Review and Update. Brazilian Archives of Digestive Surgery, 30, 150-154. [Google Scholar] [CrossRef] [PubMed]
|
|
[41]
|
De Angelis, C., Cortegoso Valdivia, P., Venezia, L., et al. (2018) Diagnosis and Management of Zollinger-Ellison Syndrome in 2018. Minerva Endocrinologica, 43, 212-220. [Google Scholar] [CrossRef]
|
|
[42]
|
Basuroy, R., Haji, A., Ramage, J.K., et al. (2016) Review Article: The Investigation and Management of Rectal Neuroendocrine Tumours. Alimentary Pharmacology & Therapeutics, 44, 332-345. [Google Scholar] [CrossRef] [PubMed]
|
|
[43]
|
Cummings, D., Wong, J., Palm, R., et al. (2021) Epidemiology, Diagnosis, Staging and Multimodal Therapy of Esophageal and Gastric Tumors. Cancers, 13, Article No. 582. [Google Scholar] [CrossRef] [PubMed]
|
|
[44]
|
Kulke, M.H., Anthony, L.B., Bushnell, D.L., et al. (2010) NANETS Treatment Guidelines: Well-Differentiated Neuroendocrine Tumors of the Stomach and Pancreas. Pancreas, 39, 735-752. [Google Scholar] [CrossRef]
|
|
[45]
|
Pavel, M., Öberg, K., Falconi, M., et al. (2020) Gastroenteropancreatic Neuroendocrine Neoplasms: ESMO Clinical Practice Guidelines for Diagnosis, Treatment and Follow-Up. Annals of Oncology: Official Journal of the European Society for Medical Oncology, 31, 844-860. [Google Scholar] [CrossRef] [PubMed]
|
|
[46]
|
Massironi, S., Zilli, A. and Conte, D. (2015) Somatostatin Analogs for Gastric Carcinoids: for Many, but Not All. World Journal of Gastroenterology, 21, 6785-6793. [Google Scholar] [CrossRef] [PubMed]
|
|
[47]
|
Boyce, M., Moore, A.R., Sagatun, L., et al. (2017) Netazepide, a Gastrin/Cholecystokinin-2 Receptor Antagonist, Can Eradicate Gastric Neuroendocrine Tumours in Patients with Autoimmune Chronic Atrophic Gastritis. British Journal of Clinical Pharmacology, 83, 466-475. [Google Scholar] [CrossRef] [PubMed]
|
|
[48]
|
Rossi Re Massironi, S., Conte, D., et al. (2014) Therapy for Metastatic Pancreatic Neuroendocrine Tumors. Annals of Translational Medicine, 2, 8.
|
|
[49]
|
Ramage, J.K., Ahmed, A., Ardill, J., et al. (2012) Guidelines for the Management of Gastroenteropancreatic Neuroendocrine (Including Carcinoid) Tumours (NETs). Gut, 61, 6-32. [Google Scholar] [CrossRef] [PubMed]
|
|
[50]
|
Xu, J., Li, J., Bai, C., et al. (2019) Surufatinib in Advanced Well-Differentiated Neuroendocrine Tumors: A Multicenter, Single-Arm, Open-Label, Phase Ib/II Trial. Clinical Cancer Research: An Official Journal of the American Association for Cancer Research, 25, 3486-3494. [Google Scholar] [CrossRef]
|
|
[51]
|
Yao, J.C., Shah, M.H., Ito, T., et al. (2011) Everolimus for Advanced Pancreatic Neuroendocrine Tumors. The New England Journal of Medicine, 364, 514-523. [Google Scholar] [CrossRef]
|
|
[52]
|
Crosby, D.A., Donohoe, C.L., Fitzgerald, L., et al. (2012) Gastric Neuroendocrine Tumours. Digestive Surgery, 29, 331-348. [Google Scholar] [CrossRef] [PubMed]
|
|
[53]
|
Jenny, H.E., Ogando, P.A., Fujitani, K., et al. (2016) Laparoscopic Antrectomy: A Safe and Definitive Treatment in Managing Type 1 Gastric Carcinoids. American Journal of Surgery, 211, 778-782. [Google Scholar] [CrossRef] [PubMed]
|
|
[54]
|
Scher Bl, H., Jensen, R.T., Cadiot, G., et al. (2011) Management of Early Gastrointestinal Neuroendocrine Neoplasms. World Journal of Gastrointestinal Endoscopy, 3, 133-139. [Google Scholar] [CrossRef] [PubMed]
|
|
[55]
|
Rappel, S., Altendorf-Hofmann, A. and Stolte, M. (1995) Prognosis of Gastric Carcinoid Tumours. Digestion, 56, 455-462. [Google Scholar] [CrossRef] [PubMed]
|
|
[56]
|
Chen, W.C., Warner, R.R., Ward, S.C., et al. (2015) Management and Disease Outcome of Type I Gastric Neuroendocrine Tumors: The Mount Sinai Experience. Digestive Diseases and Sciences, 60, 996-1003. [Google Scholar] [CrossRef] [PubMed]
|